ONWARD Medical NV
F:63E
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
O
|
ONWARD Medical NV
F:63E
|
NL |
|
Avi Ltd
F:IZ60
|
ZA |
|
Technip Energies NV
OTC:THNPF
|
FR |
|
A
|
Altria Group Inc
XBER:PHM7
|
US |
|
A
|
Arlo Technologies Inc
SWB:2VI
|
US |
ONWARD Medical NV
ONWARD Medical develops implantable and external neurostimulation devices that are designed to help people with spinal cord injury and related movement disorders recover motion and function. Its main products are built around electrical stimulation of the spinal cord, which aims to activate nerve pathways that still exist but no longer work properly after injury. The company focuses on therapies that can support walking, hand use, blood pressure control, and other functions affected by spinal cord damage. The company sells its technology to hospitals, doctors, rehabilitation centers, and research partners, and it also works through clinical programs that support future adoption of its devices. It makes money by selling medical devices and related systems, and by moving its therapies through clinical development toward broader medical use. Its business sits between medical device engineering and neurorehabilitation, which means it is not just making hardware but building a treatment approach around that hardware. What makes ONWARD’s business different is that it is trying to turn spinal cord stimulation into a practical therapy for daily life, not just a research tool. Instead of treating symptoms with drugs, it uses targeted electrical signals to help the nervous system regain lost function. That puts the company in a specialized corner of the medtech industry where success depends on clinical evidence, physician adoption, and the ability to make complex neurotechnology usable in real care settings.
ONWARD Medical develops implantable and external neurostimulation devices that are designed to help people with spinal cord injury and related movement disorders recover motion and function. Its main products are built around electrical stimulation of the spinal cord, which aims to activate nerve pathways that still exist but no longer work properly after injury. The company focuses on therapies that can support walking, hand use, blood pressure control, and other functions affected by spinal cord damage.
The company sells its technology to hospitals, doctors, rehabilitation centers, and research partners, and it also works through clinical programs that support future adoption of its devices. It makes money by selling medical devices and related systems, and by moving its therapies through clinical development toward broader medical use. Its business sits between medical device engineering and neurorehabilitation, which means it is not just making hardware but building a treatment approach around that hardware.
What makes ONWARD’s business different is that it is trying to turn spinal cord stimulation into a practical therapy for daily life, not just a research tool. Instead of treating symptoms with drugs, it uses targeted electrical signals to help the nervous system regain lost function. That puts the company in a specialized corner of the medtech industry where success depends on clinical evidence, physician adoption, and the ability to make complex neurotechnology usable in real care settings.
Record Revenue: ONWARD reported its highest-ever quarterly revenue of EUR 1.7 million, reflecting strong commercial momentum.
Regulatory Milestones: The company received CE Mark for ARC-EX in Europe, FDA clearance for U.S. home use, and UL Mark certification, expanding both clinical and home market opportunities.
Clinic Adoption: ARC-EX systems are now in over 60 U.S. clinics, with 40 units sold in Q3 and strong utilization rates reported.
Capital Raise: ONWARD raised over EUR 50 million in new equity, extending its cash runway into Q1 2027 and boosting its net cash position to EUR 77.7 million after the quarter.
European Launch: Commercial rollout began in Germany, Switzerland, Austria, the Netherlands, and the UK, with first European sales expected in Q4.
Home Use Acceleration: U.S. home use clearance sparked a threefold increase in inbound leads; pricing is set about 25% lower than clinic devices to improve access.
Clinical Pipeline: Empower BP pivotal study for ARC-IM has begun site activation, with first enrollment expected soon and potential interim efficacy analysis by late summer.
Strong Demand & Growth Outlook: Management expects robust demand to sustain in Q4 and sees potential for revenue to more than double or triple next year if consensus is met.
